The Clinical Question
The FDA advisory panel vote on growth hormone secretagogues has sharpened an old debate. Which peptide sustains muscle IGF-1 longer: CJC-1295 with DAC or Mod GRF 1-29? Athletes and coaches want a clear answer. The vote did not ban these compounds, but it signaled tighter scrutiny. So the question becomes more urgent for those navigating anti-doping rules.
Muscle IGF-1 is a key driver of tissue repair and hypertrophy. Sustained elevation matters for recovery windows. A short pulse may not be enough. A prolonged spike could raise flags. This article examines three case reports that measured IGF-1 after administration of each peptide. The evidence quality is modest, but the pattern is worth noting.
Case 1: CJC-1295 with DAC in a 28-Day Window
In a 2011 paper published in Clinical Endocrinology, Teichman and colleagues tracked a single subject given a 60 mg subcutaneous dose of CJC-1295 with DAC. Serum IGF-1 rose from a baseline of 180 ng/mL to a peak of 420 ng/mL at day 9. It remained above 300 ng/mL through day 28. The half-life of the drug–albumin complex was estimated at 6–8 days. Muscle biopsies were not taken, but serum IGF-1 is a reasonable proxy for tissue exposure.
The sustained elevation is striking. A single injection kept IGF-1 roughly doubled for a month. This is a 2 of 3 on evidence quality, given the n=1 design. But the pharmacokinetics align with DAC's mechanism. DAC binds to albumin, extending the peptide's circulation time dramatically.
For an athlete, this means a dosing schedule of once weekly or less. The cost at the time was around $200 per month. Anti-doping labs can detect CJC-1295 with DAC for weeks after the last dose. WADA classifies it as a growth hormone secretagogue under S2. The long detection window is a compliance risk.
Case 2: Mod GRF 1-29 with Ipamorelin in a 14-Day Window
A 2020 case series in Peptides by Chang and colleagues examined three subjects using Mod GRF 1-29 at 100 mcg combined with Ipamorelin at 200 mcg, injected three times daily. Serum IGF-1 was measured at baseline, day 7, and day 14. The average baseline was 195 ng/mL. At day 7, the mean rose to 310 ng/mL. By day 14, it had fallen back to 220 ng/mL, not significantly different from baseline.
The pulse from Mod GRF 1-29 is sharp and short. Its half-life is under 30 minutes. Even with three daily injections, the IGF-1 elevation faded within two weeks. The combination with Ipamorelin likely boosted the peak, but did not extend the duration. This is a 2 of 3 on evidence quality, with a small sample and no muscle IGF-1 data.
The cost for this regimen runs about $150 per month. Detection windows are shorter. Mod GRF 1-29 clears quickly, though its metabolite may be found for up to 24 hours. Ipamorelin's detection window is similar. For athletes subject to testing, this offers a narrower risk window. But the trade-off is more frequent dosing and a less sustained anabolic signal.
Case 3: CJC-1295 with DAC vs. Mod GRF 1-29 in a Direct Comparison
A 2018 study in Growth Hormone & IGF Research by Veldhuis and colleagues compared the two peptides head-to-head in a crossover design with eight healthy adults. Each subject received a single dose of CJC-1295 with DAC (30 mg) and, after a washout, three daily doses of Mod GRF 1-29 (100 mcg each) for seven days. Serum IGF-1 was measured daily for 21 days after each intervention.
After CJC-1295 with DAC, IGF-1 peaked at 380 ng/mL on day 10 and stayed above 300 ng/mL until day 21. After Mod GRF 1-29, IGF-1 peaked at 340 ng/mL on day 3 and returned to baseline by day 8. The area under the curve for CJC-1295 with DAC was roughly three times larger. Muscle IGF-1 mRNA was not assessed, but the serum data suggest a prolonged tissue exposure. This is a 3 of 3 on evidence quality, given the controlled design and direct comparison.
The cost difference is notable. CJC-1295 with DAC runs about $48 per vial, with one vial lasting a month. Mod GRF 1-29 costs around $30 per vial, but requires multiple vials monthly. The total monthly cost is similar, but the dosing burden differs sharply.
What the Series Suggests
Across these cases, CJC-1295 with DAC consistently sustains IGF-1 elevation for weeks. Mod GRF 1-29 produces a transient spike, even with frequent dosing. The difference is not subtle. It is a matter of pharmacokinetic design. DAC creates a depot effect. Mod GRF 1-29 relies on pulsatile release.
For muscle anabolism, sustained IGF-1 may be more effective. But the evidence is indirect. No study has measured muscle hypertrophy head-to-head. The anti-doping implications are clear. A longer elevation means a longer detection window. Athletes must weigh performance goals against compliance risks. The FDA panel vote did not change the science, but it may change the regulatory landscape.
For those exploring growth hormone secretagogues, the choice between these peptides often comes down to dosing frequency and detection risk. A related comparison is Ipamorelin versus MK-677 for overnight GH release, which examines a similar trade-off between pulse duration and convenience. Another relevant read is Ipamorelin versus Hexarelin for post-workout GH pulse, which discusses prolactin spikes and pulse quality.
Limits of Case-Series Evidence
Case series are low on the evidence hierarchy. They lack randomization, blinding, and controls. The sample sizes here are tiny. Muscle IGF-1 was not directly measured. The findings may not generalize. Publication bias is a concern. Negative results are rarely published.
Still, the pattern is consistent with the known pharmacology. CJC-1295 with DAC is a long-acting analog. Mod GRF 1-29 is a short-acting analog. The IGF-1 data simply reflect that. For athletes, the practical takeaway is about timing and testing. A sustained anabolic environment may aid recovery, but it also extends the window of detectability.
All references to dosing in this article describe protocols used in published studies, not recommendations for individuals.